ISRG vs RMTI vs SKYA Stock Comparison

Intuitive Surgical, Rockwell Medical and SkyAI Prices as of Nov 5, 2026 Peers: Industry group
1 more company in this comparison (DXCM) Create a free account to keep reading and compare up to 10 companies.
ISRG Intuitive Surgical Inc
$468.52 +15.8% 1M -14.6% 1Y
Market cap
$158.52B
P/E
53.6x
Revenue (TTM)
$11.58B
Div. yield
–
Medical Devices Healthcare
4 wins
RMTI Rockwell Medical, Inc.
$7.60 -1.3% 1M +630.8% 1Y
Market cap
$30.17M
P/E
–
Revenue (TTM)
$69.39M
Div. yield
–
Medical Supplies Healthcare
2 wins
SKYA SkyAI, Inc.
$2.92 +55.3% 1M -30.6% 1Y
Market cap
$212.68M
P/E
–
Revenue (TTM)
$174.18K
Div. yield
–
Medical Supplies Healthcare
2 wins

Head to Head

8 decided of 12

Intuitive Surgical leads on 4 of the 12 questions below (Intuitive Surgical 4, SkyAI 2, Rockwell Medical 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionISRGRMTISKYALeader
Larger companyMarket capitalisation $158.52B $30.17M $212.68M ISRG
Cheaper on earningsLower P/E, profitable companies only 53.6x -5.9x -0.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 40.7x — 0.0x SKYA
Faster revenue growthRevenue growth, trailing twelve months +20.5% -21.1% +108.0% SKYA
More profitableNet margin, trailing twelve months 25.5% -7.3% -228,220.7% ISRG
Better return on capitalReturn on invested capital — — — –
Less leveragedLower net debt / EBITDA — 7.8x — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -14.6% +630.8% -30.6% RMTI
Better 5-year returnAnnualised price return, 5 years +5.1%/yr +5.4%/yr — RMTI
Less volatileAnnualised volatility, 1 year 35.9% 402.1% 104.7% ISRG
Higher overall scoreMean of the five percentile scores vs peers 79/100 56/100 27/100 ISRG

Percentile Scorecard

ISRGRMTISKYA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisISRGRMTISKYA
Valuation 47 #123 of 229 90 #25 of 229 4 #221 of 229
Growth 81 #44 of 221 24 #168 of 221 4 #213 of 221
Profitability 97 #7 of 210 56 #93 of 210 1 #209 of 210
Financial Health 81 #47 of 240 55 #109 of 240 95 #13 of 240
Shareholder Returns 93 #12 of 147 – 33 #99 of 147
Overall 79 56 27
  • ISRG ranked among 247 companies in Medical Devices and Diagnostics
  • RMTI ranked among 247 companies in Medical Devices and Diagnostics
  • SKYA ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodISRGRMTISKYASPY
1 month +15.8%-1.3%+55.3% -5.9%
3 months +25.4%+6.1%+149.6% -4.6%
6 months +3.3%+874.4%+56.1% +0.2%
Year to date -17.3%+815.7%+43.8% +7.5%
1 year -14.6%+630.8%-30.6% +8.2%
3 years +69.0%+293.8%-99.9% +68.3%
3 years, per year +19.1%+58.0%-90.0% +19.0%
5 years +28.4%+30.4%— +56.5%
5 years, per year +5.1%+5.4%— +9.4%
10 years +528.0%-87.8%— +251.5%
10 years, per year +20.2%-19.0%— +13.4%

Risk

MeasureISRGRMTISKYASPY
Volatility, 1Y 35.9%402.1%104.7% 13.6%
Downside volatility, 1Y 38.0%353.1%104.1% 14.2%
Beta vs S&P 500, 1Y 0.931.632.15 1.00
Return / volatility, 1Y -0.411.57-0.29 0.60
Max drawdown, 5Y -49.9%-91.1%-100.0% -25.4%
From 52-week high -21.0%-14.1%-30.6% -5.9%
52-week high $592.85$8.85$4.21 $779.14
52-week low $332.02$0.55$0.95 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleISRGRMTISKYA
P/E now vs peer median 55.3xmedian 26.9x -5.9xmedian 26.9x -0.5xmedian 26.9x
P/S now vs peer median 14.0xmedian 2.9x 0.4xmedian 2.9x 1,209xmedian 2.9x
EV/EBITDA now vs peer median 38.7xmedian 17.5x -7.1xmedian 17.5x -0.5xmedian 17.5x
P/FCF now vs peer median 45.1xmedian 26.4x 20.1xmedian 26.4x -1.0xmedian 26.4x
P/B now vs peer median 10.1xmedian 2.3x 0.9xmedian 2.3x 1.3xmedian 2.3x
PEG now vs peer median 2.15median 0.88 -0.14median 0.88 0.01median 0.88

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsISRGRMTISKYA
Revenue $11.58B $69.39M $174.18K
Gross profit $7.78B $12.29M $324.68K
Operating income $3.28B -$4.52M -$374.36M
Net income $2.97B -$5.08M -$397.51M
Free cash flow $3.60B $1.50M -$201.93M
R&D $1.49B $40.00K $475.55K
EPS (diluted) $8.41 $-1.28 $-5.51
Cash & equivalents $2.98B $10.52M $12.07M
Total debt – $9.00M –
Shares (diluted) 351.60M 3.96M 72.09M
Enterprise value $138.81B -$67.22M $167.38M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricISRGRMTISKYA
P/E 55.3x -5.9x -0.5x
P/FCF 45.1x 20.1x -1.0x
P/Operating cash flow 39.7x 10.6x -14.6x
P/S 14.0x 0.4x 1,209x
P/B 10.1x 0.9x 1.3x
P/Tangible book 10.9x 1.2x 16.2x
EV/EBITDA 38.7x -7.1x -0.5x
EV/EBIT 48.2x -3.2x -0.5x
EV/Revenue 13.7x 0.2x 1,139x
EV/FCF 44.0x 9.6x -1.0x
EV/Operating cash flow 38.7x 5.0x -13.8x
PEG (3Y EPS CAGR) 2.15 -0.14 0.01

Growth

14 metrics
MetricISRGRMTISKYA
Revenue growth (1Y) 20.5% -21.1% 108.0%
Revenue CAGR (3Y) 19.1% -2.9% 19.4%
Gross profit growth (1Y) 21.9% -20.3% –
Gross profit CAGR (3Y) 19.5% 22.1% –
Operating income growth (1Y) 16.6% -250.1% -8,055%
Operating income CAGR (3Y) 24.8% 23.4% -240.7%
Net income growth (1Y) 7.5% -142.2% -54,854%
Net income CAGR (3Y) 24.4% 24.1% -268.2%
EPS growth (1Y) 10.8% -109.9% -658.6%
EPS CAGR (3Y) 25.7% 41.1% -100.6%
Operating cash flow growth (1Y) 38.1% -18.3% -356.8%
Operating cash flow CAGR (3Y) 26.4% 34.2% -24.4%
Free cash flow growth (1Y) 58.4% -44.2% -6,031%
Free cash flow CAGR (3Y) 42.0% 30.2% -196.9%

Profitability

14 metrics
MetricISRGRMTISKYA
Gross margin 67.2% 17.7% 186.4%
EBITDA margin 35.3% -2.9% -214,892%
Operating margin 28.4% -6.5% -214,931%
Pretax margin 31.3% -7.9% -221,236%
Net margin 25.5% -7.3% -228,221%
FCF margin 31.1% 2.2% -115,934%
Operating cash flow margin 35.3% 4.1% -8,259%
Return on equity 17.3% -15.5% -280.7%
Return on assets 14.8% -9.6% -276.3%
Return on invested capital – – –
Return on capital employed 18.7% -9.9% -223.1%
Asset turnover 0.6x 1.2x 0.0x
Cash conversion (OCF / net income) 1.4x -0.6x 0.0x
Stock comp / revenue 7.2% 2.7% 52,451%

Financial Health

11 metrics
MetricISRGRMTISKYA
Debt / assets – 15.9% –
Debt / equity – 0.3x –
Net debt / EBITDA – 7.8x –
Debt / FCF – 6.0x –
Liabilities / assets 16.7% 37.9% 1.9%
Equity / assets 83.3% 62.1% 98.1%
Interest coverage – -4.0x –
Current ratio 3.3x 3.3x 5.3x
Quick ratio 2.3x 3.0x 4.4x
Cash ratio 1.6x 2.2x 4.2x
Altman Z-score 32.00 -7.71 29.80

Shareholder Returns

7 metrics
MetricISRGRMTISKYA
Dividend yield – – –
Net buyback yield 2.6% – -0.6%
Shareholder yield 2.6% – -0.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusISRGRMTISKYA
Forward P/E 40.7xFY2026 – 0.0xFY2026
EPS, next fiscal year $11.51FY2026 $-0.97FY2026 $2,362.06FY2026
EPS growth, next FY +28.9%FY2026 – –
EPS growth, the year after +4.5% – –
Revenue, next fiscal year $11.61BFY2026 $77.07MFY2026 $70.01MFY2026
Revenue growth, next FY +15.4%FY2026 +11.3%FY2026 +34,200.1%FY2026
Revenue growth, the year after +11.2% +7.5% +17.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersISRGRMTISKYA
Held by institutions 86.2% 8.6% –
Institutions holding 2,240 33 –
Change in shares held, QoQ +4.6% -14.2% –
Institutions buying 1,072 13 –
Institutions selling 879 9 –
Buyers to sellers 1.22 1.44 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ISRGRMTISKYA
ISRG 1.00 0.07 0.14
RMTI 0.07 1.00 0.04
SKYA 0.14 0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ISRG, RMTI and SKYA?

Intuitive Surgical (ISRG) is the largest by market capitalisation: Intuitive Surgical (ISRG) $158.52B, Rockwell Medical (RMTI) $30.17M, SkyAI (SKYA) $212.68M.

Which company is growing faster?

SkyAI (SKYA) grew revenue fastest over the trailing twelve months: Intuitive Surgical (ISRG) +20.5%, Rockwell Medical (RMTI) -21.1%, SkyAI (SKYA) +108.0%.

Which company is more profitable?

Intuitive Surgical (ISRG) has the highest net margin (Intuitive Surgical (ISRG) 25.5%, Rockwell Medical (RMTI) -7.3%, SkyAI (SKYA) -228,220.7%).

Which stock has performed better?

Over the past year Rockwell Medical (RMTI) returned the most: Intuitive Surgical (ISRG) -14.6%, Rockwell Medical (RMTI) +630.8%, SkyAI (SKYA) -30.6%. Over five years, Rockwell Medical (RMTI) compounded fastest (Intuitive Surgical (ISRG) +5.1%/yr, Rockwell Medical (RMTI) +5.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Intuitive Surgical (ISRG) has been the steadiest (Intuitive Surgical (ISRG) 35.9%, Rockwell Medical (RMTI) 402.1%, SkyAI (SKYA) 104.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ISRG, RMTI and SKYA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Intuitive Surgical (ISRG) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.